\
&
Contact us
\
&
Contact us
Published on | 9 months ago
Programmes Deployment: Best use of technologiesThe European Commission (DG CONNECT) has launched the following procurement procedure:
Better Internet for Kids (BIK) Platform – EU Coordination (EC-CNECT/LUX/2024/OP/0097)
The EU-funded Better Internet for Kids portal (at https://better-internet-for-kids.europa.eu) and the associated coordination tasks are the main subject of this call for tender. The BIK portal will cater to the needs of a community of Safer Internet Centres and support them in the delivery of online safety services aimed at children. This EU hub for child online safety is a key tool to support the European Commission in the implementation of the European strategy for a better internet for kids (‘Better Internet for Kids’, ‘BIK+ strategy’) (COM (2022)212) at national, European and international level.
Estimated value excluding VAT: €4,000,000
More information can be found on the Funding & Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
